NPS investors go long on positive Phase III short bowel results
This article was originally published in Scrip
Executive Summary
Investors 31 January drove shares of NPS Pharmaceuticals as high as 34%, or $2.56, after the firm reported that its recombinant analogue of human glucagon-like peptide 2 (GLP-2), Gattex (teduglutide), reduced parenteral-nutrition (PN) dependence in adults with short-bowel syndrome (SBS) in a pivotal Phase III study – results analysts said almost assure the drug's US approval.